UGDH: Enzyme Involved in Uridine and Glucose Metabolism (G7358)

Target Name: UGDH

NCBI ID: G7358

UGDH

UGDH: Enzyme Involved in Uridine and Glucose Metabolism

UGDH (Uridine diphospho-glucose dehydrogenase), also known as UGDH1 or GLDH1, is a gene that encodes a protein involved in the metabolism of uridine and glucose. The uridine and glucose metabolism are crucial for the proper functioning of the body, and the UGDH protein plays a vital role in this process.

UGDH is a member of the GDP-dependent enzyme family, which includes proteins involved in the metabolism of various metabolites, including nucleotides, phospholipids, and glucose. The GDP-dependent enzyme family is a large and diverse family that includes enzymes involved in the transfer of phosphate groups from other molecules to the GDP molecule, which is a key structural component of the cell's intracellular signaling pathways.

UGDH is expressed in many different tissues and cells throughout the body, including the brain, heart, liver, and muscle. It is also highly expressed in the liver, which is the primary organ that metabolizes uridine and glucose. The liver is responsible for producing and storing uridine, which is a byproduct of the metabolism of nucleotides. UGDH is also expressed in the muscle, where it is involved in the metabolism of muscle protein and other nutrients.

UGDH is a critical enzyme involved in the metabolism of uridine and glucose. It catalyzes the conversion of uridine to uric acid, which is then excreted from the body by the kidneys. UGDH also catalyzes the conversion of glucose to glutose, which is then transported into the liver for further metabolism. In addition, UGDH is involved in the metabolism of other nutrients, including lipids and amino acids.

The UGDH gene has been implicated in a number of diseases, including cardiovascular disease, diabetes, and certain cancers. Studies have shown that UGDH is often expressed in tissues or cells that are affected by these conditions, and that it is involved in the metabolism of compounds that are relevant to these diseases.

In addition to its role in metabolism, UGDH is also a potential drug target or biomarker. The UGDH protein has been shown to be involved in a number of cellular processes that are important for the development and progression of certain diseases. For example, UGDH has been shown to be involved in the regulation of cell proliferation, and has been implicated in the development of cancer. In addition, UGDH has also been shown to be involved in the regulation of the immune system, and has been implicated in the development of autoimmune diseases.

In conclusion, UGDH is a critical enzyme involved in the metabolism of uridine and glucose. It is expressed in many different tissues and cells throughout the body, and has been implicated in a number of diseases. As a potential drug target or biomarker, UGDH is a promising target for the development of new therapies for a variety of diseases. Further research is needed to fully understand the role of UGDH in the metabolism and regulation of uridine and glucose, and to develop effective treatments for diseases associated with its dysfunction.

Protein Name: UDP-glucose 6-dehydrogenase

Functions: Catalyzes the formation of UDP-alpha-D-glucuronate, a constituent of complex glycosaminoglycans (PubMed:21961565, PubMed:21502315, PubMed:23106432, PubMed:22123821, PubMed:25478983, PubMed:27966912, PubMed:30420606, PubMed:30457329). Required for the biosynthesis of chondroitin sulfate and heparan sulfate. Required for embryonic development via its role in the biosynthesis of glycosaminoglycans (By similarity). Required for proper brain and neuronal development (PubMed:32001716)

The "UGDH Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about UGDH comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets